Project-specific health-based exposure limit and occupational toxicology assessment support. The agreed scope may include PDE/ADE derivation, OEL derivation and OEB/OHC banding, based on the exact substance form, available evidence and intended product or workplace context.
CAS Registry Number
152-62-5
Molecular formula
C21H28O2
Molecular weight
312.4 g/mol
Drug class
Synthetic retroprogesteroneselective progestogen
Mechanism of action
Activates progesterone receptors and produces progestational effects on the endometrium and reproductive axis, supporting secretory endometrial transformation without significant androgenic or glucocorticoid activity.
Indications / reported uses
Treatment of progesterone deficiency-related menstrual disorders and secondary amenorrhoea in countries where dydrogesterone is authorised
Used with oestrogen in hormone replacement therapy to protect the endometrium in women with an intact uterus; specific indications vary by jurisdiction
Scope is agreed for the exact substance form, intended use, exposure route, workplace context and available toxicological evidence.
PDE/ADE: critical effects, point of departure and justified adjustment factors.
OEL: inhalation hazards, exposure duration and workplace conditions.
OEB/OHC: evidence-based banding where requested; a band is not a numerical OEL.
Report: scientific rationale, source data, assumptions, uncertainties and limitations.
Assessment scope
PDE/ADE and OEL/OEB assessment
ReguSight provides project-specific support for Dydrogesterone PDE/ADE, OEL and OEB/OHC assessments. This combined profile covers the Dydrogesterone Permitted Daily Exposure (PDE) report (the Dydrogesterone PDE report); Acceptable Daily Exposure (ADE) is the corresponding health-based daily exposure terminology. It also covers the Dydrogesterone Occupational Exposure Limit (OEL) report (the Dydrogesterone OEL report). PDE/ADE derivation and workplace exposure assessment are distinct scientific outputs; a band is not a numerical OEL.
Assessment may cover
PDE/ADE derivation using relevant toxicological evidence, critical effects, a justified point of departure and adjustment factors.
The EMA HBEL guideline informs PDE/ADE assessments in relevant shared-facility contexts. ECHA and HSE sources address workplace exposure limits; NIOSH provides occupational exposure-banding guidance. The applicable framework depends on the assessment question and jurisdiction.